Molecular Oncology Unit, Department of Biological Chemistry, University of Athens Medical School, 75 M. Asias Street, 11527 Athens, Greece.
Cancer Treat Rev. 2015 Jun;41(6):547-53. doi: 10.1016/j.ctrv.2015.04.009. Epub 2015 Apr 29.
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype. The absence of expression and/or amplification of estrogen and progesterone receptor as well as ERBB-2 prevent the use of currently available endocrine options and/or ERBB-2-directed drugs and indicates chemotherapy as the main current therapy. TNBC represents approximately 15% of breast cancer cases with high index of heterogeneity. Here, we review the role of androgen receptor in breast carcinogenesis and its association with alterations in the expression pattern and functional roles of regulatory molecules and signal transduction pathways in TNBC. Additionally, based on the so far preclinical and clinical published data, we evaluate the perspectives for using and/or developing androgen receptor targeting strategies for specific TNBC subtypes.
三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌亚型。雌激素和孕激素受体的缺失和/或扩增以及 ERBB-2 的缺失阻止了目前可用的内分泌选择和/或 ERBB-2 靶向药物的使用，并表明化疗是主要的当前治疗方法。TNBC 约占乳腺癌病例的 15%，具有高度异质性。在这里，我们回顾了雄激素受体在乳腺癌发生中的作用及其与 TNBC 中调节分子表达模式和功能作用以及信号转导通路改变的关系。此外，基于迄今为止的临床前和临床发表数据，我们评估了针对特定 TNBC 亚型使用和/或开发雄激素受体靶向策略的前景。
